الولايات المتحدة · منصات وبيانات · Briefing.com

Vaxcyte Surges as OPUS-1 Phase 3 Results Strengthen VAX-31 Regulatory Path (PCVX)

نشره Briefing.com · الولايات المتحدة منذ 14 ي

Vaxcyte (PCVX) is soaring today after announcing topline results from the pivotal Phase 3 OPUS-1 trial evaluating VAX-31. VAX-31 is PCVX's investigational 31-valent pneumococcal…

اقرأ المقال كاملًا على Briefing.com سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.briefing.com)

يستحق القراءة أيضًا

MarketBeat

30,000 Shares of Truist Financial Corporation $TFC Bought by Fortitude Financial LLC

Seeking Alpha

Rocky Mountain Chocolate Factory outlines strategic alternatives after $6.6M Durango sale-leaseback and $2M loan

The Motley Fool

Pre-IPO Anduril Stock Climbs 50% in 5 Months

MarketWatch

Blood clots are ‘incredibly common,’ even for pro athletes like Jalen Hurts. Here’s what to know.

Investing.com

Earnings call transcript: Zions Bancorporation tops Q3 2026 EPS forecast

CNBC